We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel Gives Nod to Novo’s Long-Acting Insulin Despite Heart Concerns
Panel Gives Nod to Novo’s Long-Acting Insulin Despite Heart Concerns
November 9, 2012
FDA advisers voted 8–4 Thursday in support of approval for Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg for Type 1 and Type 2 diabetes despite lingering worries about cardiovascular effects.